Microcap Ledger PepGen Inc. $PEPG
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 69,259,517 [10-Q 2026-08-06]
What the company doesAI summary of filing
PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides to improve the delivery of conjugated oligonucleotide therapeutics to target tissues. PepGen's lead product candidate, PGN-EDODM1, is in clinical development for myotonic dystrophy type 1 (DM1), a genetic disease with no approved therapies; the company has completed a Phase 1 study and is currently enrolling patients in a Phase 2 study, though the FDA has placed a partial clinical hold on U.S. enrollment pending review of preclinical data. The company is pre-revenue and has incurred significant losses since inception. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$35.58M | −$34.23M | $22.76M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$89.66M | −$81.64M | $60.51M | [10-K 2026-03-04] |
| FY ended Dec 2024 | — | −$89.98M | −$82.37M | $49.42M | [10-K 2026-03-04] |
- Quarterly cash burn
- −$17.12M
- Cash runway Estimate
- ~4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 32,595,737 | [10-Q 2024-11-07] |
| 2025-02-18 | 32,692,388 | [10-K 2025-02-24] |
| 2025-05-01 | 32,720,943 | [10-Q 2025-05-08] |
| 2025-08-01 | 32,799,724 | [10-Q 2025-08-07] |
| 2025-11-05 | 68,748,224 | [10-Q 2025-11-12] |
| 2026-02-26 | 69,115,292 | [10-K 2026-03-04] |
| 2026-05-06 | 69,169,215 | [10-Q 2026-05-12] |
| 2026-08-02 | 69,259,517 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-05-18; declared effective 2026-05-21 [S-3 2026-05-18]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-06 | 8-K | Results of operations; Regulation FD disclosure; Other events |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-06-22 | 8-K | Shareholder vote results |
| 2026-05-21 | 8-K | Regulation FD disclosure |
| 2026-05-18 | S-3 | Registration statement |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-03-30 | 8-K | Regulation FD disclosure; Other events |
| 2026-03-11 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $PEPG
Email me when PepGen Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.